source
- Alumis' TYK2 inhibitor flunks mid-stage lupus trial, shares drop 55%Alumis reported that its experimental TYK2 inhibitor, envudeucitinib, failed to meet any primary or secondary endpoints in a mid-stage study of systemic lupus erythematosus. The company highlighte…
- Novartis halts CD19 CAR-T trial after three deaths, Bristol Myers also pauses similar programNovartis announced a pause to its CD19-directed CAR-T cell therapy trials after three patients experienced fatal immune reactions. The company said the deaths were linked to a severe cytokine relea…